RxDoctor Payments Data

Jill Yandle

Nurse Practitioner · Matthews, NCNPI 1083133417

Payments from drug & device makers

$4,334in general payments, 2019–2025

Across 186 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$579
  • Novartis$528
  • Johnson & Johnson$513
  • Boston Scientific$496
  • Abbott$462
  • Boehringer Ingelheim$445
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,334 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$27,959
Medicare patients
242
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan376$405,232
JardianceEmpagliflozin161$154,018
EliquisApixaban132$142,727
FarxigaDapagliflozin Propanediol47$52,925
XareltoRivaroxaban16$25,710
Torsemide307$7,585
BrilintaTicagrelor12$7,136
Metoprolol Succinate312$3,809
Potassium Chloride199$3,759
Eplerenone38$2,451
Furosemide446$2,329
Spironolactone269$1,840
Carvedilol205$1,511
Atorvastatin Calcium177$1,493
Bumetanide34$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$528$405,232376 claims
Boehringer IngelheimJardiance$445$154,018161 claims
PfizerEliquis$117$142,727132 claims
AstraZenecaFarxiga, Brilinta$200$60,06159 claims
Johnson & JohnsonXarelto$513$25,71016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →